Drug discovery’s latest top-level appointments

New appointments

It’s not unusual for such a dynamic industry to have regular shake-ups in senior leadership, especially as innovative new technologies create brand new roles. The last couple of months have seen a number of high-profile job moves in drug discovery.

Dr Robert Kirby, COO and Dr Edward Stevens, CSO Metrion Biosciences

Kirby has been promoted from his role as Director of Operations, where he oversaw Metrion’s recent site move and doubling of staff headcount. Stevens has moved from Director of Drug Discovery, where he had been driving Metrion’s scientific strategy to develop new assays.

Nikos Tzagkarakis, Chief AI Officer, SiSaf

Tzagkarakis brings over 15 years’ senior leadership and data analytics experience in artificial intelligence and data architectures to SiSaf. He joins SiSaf from Metanomics where he designed the company’s economy simulation algorithm.

Eric Hardter, Associate Director, Regulatory Affairs, Boyds

With over eight years of regulatory experience, Hardter joins Boyds from global contract research organisation, The Emmes Company, where he led the regulatory strategy department.

Dr Parisa Zamiri, Chief Medical Officer, Complement Therapeutics

Zamiri joins CTx from Graybug Vision, where she held the position of Chief Medical Officer and was responsible for all clinical, statistics, regulatory and medical affairs activities.

Colin Bower, Chief Executive Officer, VivoSense

Bower has more than a decade of experience developing digital health products and bringing them to market in the roles of founder, CEO, Commercial Leader, and Director.

Tony Fraij, Chief Operating Officer; Shaguna Seth, Chief of Staff and Global PMO Leader; Katie Edgar, Senior Vice President of Corporate Strategy and Alliance Management; and Sarah Wakefield, Senior Vice President, Corporate Communications, KBI Biopharma

Fraij brings extensive experience as an operations leader of multiple global pharmaceutical and biotech companies to KBI Biopharma. In her new role, Seth will leverage more than two decades of experience in translational research, pharmaceutical development, manufacturing, and program management. Edgar’s background is in strategy and operations, business development, mergers and acquisitions, and portfolio and alliance management. Wakefield brings 20 years of experience, many of those in the healthcare and biotech industries.

Mathias Karlsson, Chief Medical Officer, Capitainer

Karlsson is a qualified physician and entrepreneur with experience in medical technology, life science and business development. He joins Capitainer from his role as CEO of Equalis.

Dr Rishi Shah, Head of Chemistry, Ubiquigent

Bringing extensive expertise in heterobifunctional molecules, Shah will support Ubiquigent’s internal drug discovery and strategic partnerships in the design, discovery, and development of DUB inhibitors, PROTACs and DUBTACs.

Dr Tomasz Kostrzewski, Chief Scientific Officer, CN Bio

Kostrzewski has more than 15 years of experience in molecular and cellular biology research. Joining CN Bio in 2015, he was promoted to Director of Biology in 2018 with responsibility for biological assay development and collaborative research projects.

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free